Risk of secondary hematologic malignancies and tolerability in patients with ovarian cancer treated with PARP inhibitors: A systematic review and meta-analysis of four phase III randomized controlled trials.

Kyaw Zin Thein,Somedeb Ball,Anita Sultan,Sriman Swarup,Myo Zaw,T. Htut,Pwint Phyu Hlaing,Yin Mon Myat,Rachana Yendala,Nicholas D'Cunha,Donald P. Quick,Lukman Aderoju Tijani

Risk of secondary hematologic malignancies and tolerability in patients with ovarian cancer treated with PARP inhibitors: A systematic review and meta-analysis of four phase III randomized controlled trials.

2019

Kyaw Zin Thein
Somedeb Ball
Anita Sultan
Sriman Swarup
Myo Zaw
T. Htut
Pwint Phyu Hlaing
Yin Mon Myat
Rachana Yendala
Nicholas D'Cunha
Donald P. Quick
Lukman Aderoju Tijani

e23056Background: Poly adenosine diphosphate ribose polymerase (PARP) inhibitors have shown to improve survival in ovarian cancer (OC) through synthetic lethality with potentiation of double-strand...

Keywords:

Meta-analysis
Randomized controlled trial
Oncology
Ovarian cancer
Pathology
Internal medicine
Medicine
Tolerability
Poly ADP ribose polymerase
in patient
Polymerase
Synthetic lethality

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations